A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

Also called NCT07843485

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07843485
  • EU CT 2026-526189-25-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07843485. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-09 (actual); primary completion 2028-10-20 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
Acronym
ZUPREME-4
Condition
Obesity or Overweight
Intervention (Combination product)
Petrelintide
Intervention (Combination product)
Placebo
Lead sponsor
Hoffmann-La Roche (class: industry)
Collaborator
Zealand Pharma (class: industry)

Record details

Record id
cardio:ct-nct07843485
Content hash
85155c39d3a6253e2ba865eafab30edcf2ff02f61efc9d21ba3c68f14a2a9d42